- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01851590
Resin vs. Amorolfine vs. Terbinafine Treatment in Onychomycosis
Efficacy of Topical Resin Lacquer, Amorolfine, and Oral Terbinafine for Treating Toenail Onychomycosis: a Prospective, Randomized, Controlled, Investigator-blinded, Parallel-group Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The aim of this prospective, investigator-blinded, randomized and controlled clinical trial is to explore potential differences between 5 % amorolfine and 30 % resin lacquer in topical treatment of onychomycosis. In addition, topical treatment methods are compared with the most effective 'drug of choice' for onychomycosis according the current guidelines i.e. oral medication with terbinafine.
Altogether 90 patients (the aim is to collect the 30 patients per group) who have culture or potassium hydroxide (KOH) stain verified dermatophyte onychomycosis are randomly allocated into 3 treatment groups to receive either topical treatment or oral medication for toenail onychomycosis classified as follows:
- White superficial onychomycosis (WSO)
- Distal and lateral subungual onychomycosis (DLSO)
- Proximal subungual onychomycosis (PSO)
- [Total dystrophic onychomycosis) (TDO)] [Excluded]
- [Candidal onychomycosis] [Excluded]
Participants are randomized into 3 groups to receive:
- Topical treatment: 30 % resin lacquer (Abicin®) applied once daily for 9 months.
- Topical treatment: 5 % amorolfine lacquer (Loceryl®) applied once weekly for 9 months.
- Oral medication: 250 mg terbinafine taken orally once daily for 3 months.
All patients visit at outpatient department before the launch of the study, and 3 and 9 months thereafter. Clinical examination is done by 4 physicians. During the 42-week study period, laboratory tests are conducted on samples collected before treatment, at 20 weeks, and at 42 weeks. The tests include a fungal culture, KOH staining of the toenail sample, and blood tests. Cultures and KOH microscopy are performed in an independent, specialised mycology laboratory with standard techniques (Medix Laboratories Ltd., Helsinki, Finland). The blood tests measure plasma γ-glutamyl transferase levels (also at 2 weeks); plasma creatinine levels; the total number of white blood cells, including neutrophils, monocytes, basophils, lymphocytes, and eosinophils; the total number of red blood cells, including erythrocytes and haematocrit; erythrocyte indices, including the mean corpuscular volume, mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration, and haemoglobin level; and the total number thrombocytes (initially and at 42 weeks). During the control visits, sequential digital photographs of the most disfigured and brittle toenails are acquired.
In the three phone calls, patients are asked about potential treatment-related side effects, compliance with treatment, patients' perception of treatment outcome, and their willingness to continue in the study. In each treatment arm, the treatment regimen is discontinued 5 weeks before the last toenail sampling to provide an appropriate washout period before the final culture and KOH analysis.
To ensure safety and to assess potential contraindications for the treatment regimens, all patients included in the study undergo a comprehensive medical interview and physical examination. To identify patients who may develop intolerable adverse events due to drug combinations, all concurrent medications are cross-checked to verify compatibility with resin, amorolfine, and terbinafine regimens at the beginning of the study. All patients are informed of the possibility of developing a hypersensitivity to resin, amorolfine, or terbinafine. If patients experienced symptoms that corresponded to any level of hypersensitivity, they are dropped from the study.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Vääksy, Finland, FI-17200
- Vääksyn Lääkärikeskus
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Positive dermatophyte culture in the beginning of the study obtained from the toenail sample.
- Positive KOH stain in the beginning of the study obtained from the toenail sample.
Exclusion Criteria:
- Any other nail disease than dermatophyte culture or KOH stain verified onychomycosis
- Onychomycosis caused by yeasts or nondermatophyte molds
- Kidney failure determined by plasma creatinine level (P-Krea > 100 μmol/l)
- Liver failure determined by plasma γ-glutamyltransferase level (P-GT > 120 U/I)
- Sensitivity or allergy to Resin, Amorolfine or Terbinafine
- Potential adverse cross-reaction of Terbinafine, Amorolfine or Resin with the patient's permanent medication
- Presence of total dystrophic onychomycosis (TDO)
- Any topical or oral antifungal treatment within the 6 months before the beginning of the study (washout period > 6 months).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Resin Lacquer
Topical 30% Resin Lacquer applied once daily for 9 months (Abicin® 30% Nail Lacquer).
|
30% Resin Lacquer is applied once daily for 9 months (Abicin®) in toenail onychomycosis.
Other Names:
|
Active Comparator: Amorolfine
Topical 5% Amorolfine Lacquer applied once weekly for 9 months (Loceryl® 5% Nail Lacquer).
|
5% Amorolfine Lacquer is applied once weekly for 9 months (Loceryl®) in toenail onychomycosis.
Other Names:
|
Active Comparator: Terbinafine
250 mg of Terbinafine taken orally once daily for 3 months (Generics).
|
250 mg of Terbinafine is taken orally once daily for 3 months (Generics) in toenail onychomycosis.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mycological Cure
Time Frame: At 4- and 10 months time-points from the beginning of the study.
|
To analyze the rate of complete mycological cure i.e. fungal eradication in terms of negative mycological culture AND negative potassium hydroxide (KOH) stain at 4- and 10 months time-points from the beginning of the study.
|
At 4- and 10 months time-points from the beginning of the study.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Responses to the Treatments
Time Frame: At 4- and 10 months time-points from the beginning of the study.
|
Clinical responses to treatment were based on the proximal linear growth of healthy nail; thus, the clinical responses were classified as partial (evident proximal linear growth of healthy nail) or complete.
Partial responses were defined as significant reductions in onycholysis, subungual hyperkeratosis, and streaks.
A complete response was a fully normal appearance of the toenail.
|
At 4- and 10 months time-points from the beginning of the study.
|
Cost-effectiveness 1
Time Frame: At 10-month time-point
|
Cost analysis was based on the retail price (€) and consumption of a 10 ml bottle of Abicin® 30% resin lacquer, a 5 ml bottle of Loceryl® 5% amorolfine lacquer, and 98 tablets of generic 250 mg terbinafine, sold by the University Pharmacy in Helsinki, Finland, January 2014.
The cost was expressed as the average treatment cost per patient; for the total cost, this average was extrapolated to the entire study treatment arm.
The results show the treatment costs (€) per day per patient in each group.
|
At 10-month time-point
|
Cost-effectiveness 2
Time Frame: At 10-month time-point
|
Cost analysis was based on the retail price (€) and consumption of a 10 ml bottle of Abicin® 30% resin lacquer, a 5 ml bottle of Loceryl® 5% amorolfine lacquer, and 98 tablets of generic 250 mg terbinafine, sold by the University Pharmacy in Helsinki, Finland, January 2014.
The cost was expressed as the average treatment cost per patient; for the total cost, this average was extrapolated to the entire study treatment arm.
The results show the treatment costs (€) during the treatment period per patient in each group.
|
At 10-month time-point
|
Compliance to the Treatment
Time Frame: At 4-month time-point
|
Evaluation of compliance was based on patient self-reports of whether the treatment protocol was followed 100% (complete), 80% (good), 60% (moderate), or 40% (poor) of the time.
|
At 4-month time-point
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Janne J. Jokinen, MD, PhD, Department of Cardiac Surgery, Heart and Lung Centre, Helsinki University Hospital, FI-00029, Helsinki, Finland
Publications and helpful links
General Publications
- Sigurgeirsson B et al. Efficacy of amorfine nail lacquer for the prophylaxis of onychomycosis over 3 years. J Eur Acad Dermatol Venereol 2010;24: 910-5. Rautio M et al. Antibacterial effects of home-made resin salve from Norway spruce (Picea abies). APMIS 2007;115: 335-340. Rautio M et al. In vitro fungistatic effects of natural coniferous rosin from Norway spruce (Picea abies). Eur J Clin Microbiol Infect Dis 2012;31:1783-9. Sipponen A et al. Effects of Norway spruce (Picea abies) resin on cell wall and cell membrane of Staphylococcus aureus. Ultrastruct Pathol 2009;33: 128-135. Sipponen P et al. Natural coniferous resin lacquer in treatment of toenail onychomycosis: an observational study. Mycoses 2012, Accepted. Roberts DT et al. British Association of Dermatologists. Guidelines for treatment of onychomycosis. Br J Dermatol 2003;148:402-10. Baran R et al. A new classification of onychomycosis. Br J Dermatol 1998;139: 567-71.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 334/13/03/01/2012
- 2012-004822-48 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Onychomycosis
-
Vésale HospitalJanssen-Cilag Ltd.CompletedPrevalence of Onychomycosis | Diabetic Neuropathic Patients | Diagnostic of Onychomycosis | Patients Clinically Suspected of Onychomycosis | Reliability of the Diagnosis of OnychomycosisBelgium
-
University of Alabama at BirminghamDUSA Pharmaceuticals, Inc.CompletedToenail Onychomycosis | Distal and Lateral Subungual Toenail OnychomycosisUnited States
-
DeviceFarm, Inc.Symbio, LLC; Center for Dermatology Clinical Research, Inc.CompletedOnychomycosis Due to Trichophyton Rubrum | Onychomycosis Due to Trichophyton MentagrophytesUnited States
-
Janssen Korea, Ltd., KoreaCompleted
-
ToeFX Inc.Active, not recruiting
-
SATO Pharmaceutical Co., Ltd.Active, not recruitingOnychomycosis of ToenailUnited States
-
Mahidol UniversityCompletedNon-dermatophyte OnychomycosisThailand
-
Oystershell NVCompletedOnychomycosis of ToenailTunisia
-
Moberg Pharma ABCompletedDistal Subungual OnychomycosisUnited States, Canada
-
PfizerCompletedOnychomycosis of ToenailsUnited States, Canada
Clinical Trials on Resin Lacquer
-
University of MalagaWithdrawn
-
Brasilia University HospitalUnknown
-
Galderma R&DCompleted
-
University of LeedsUnknownPostoperative Sensitivity of Existing Dental Filling MaterialsUnited Kingdom
-
Alshimaa Nasser MahmoudCompletedPreheating of Resin CompositeEgypt
-
Istanbul Medipol University HospitalKuraray Noritake Dental Inc.Active, not recruitingDenture, Partial, Fixed, Resin-Bonded | Tooth Loss / Rehabilitation | Resin CementsTurkey
-
Nuh Naci Yazgan UniversityTC Erciyes UniversityCompleted
-
University of GenovaUnknown
-
Universidade Federal do ParaCompletedNon Carious Cervical LesionBrazil
-
Ain Shams UniversityOctober University for Modern Sciences and ArtsNot yet recruiting